GNLX
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
Genelux Corporation (GNLX) is rated D+ (1.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Value (F). The rating has held at D+ for 7 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-12 | F (0.0) | C- (1.9) | D+ (1.8) | C- (2.0) | C+ (2.6) | D+ (1.7) |
| 2026-11-05 | F (0.0) | C- (1.9) | D+ (1.8) | C- (2.1) | C+ (2.7) | D+ (1.7) |
| 2026-10-29 | F (0.0) | C- (1.9) | C- (1.9) | C- (2.0) | C+ (2.7) | D+ (1.7) |
| 2026-10-22 | F (0.0) | C- (1.9) | D+ (1.8) | C- (1.9) | C+ (2.6) | D+ (1.7) |
| 2026-10-15 | F (0.0) | C- (1.9) | D+ (1.8) | C- (2.1) | C+ (2.6) | D+ (1.7) |